May 4th 2020
Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.
May 3rd 2020
Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.
The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.
May 2nd 2020
Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.
Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.